Skip to main content
Rocket Doctor AI Inc. logo

Rocket Doctor AI Inc. — Investor Relations & Filings

Ticker · AIDR ISIN · CA7729241066 CSE Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 346 across all filing types
Latest filing 2024-12-24 Share Issue/Capital Cha…
Country CA Canada
Listing CSE AIDR

About Rocket Doctor AI Inc.

https://www.rocketdoctor.ai/

Rocket Doctor AI Inc. is a healthcare technology company specializing in medical AI solutions designed to improve patient care accessibility and outcomes across the full patient journey. The company delivers physician-built, AI-powered tools, including healthcare APIs and a proprietary "AI brain" that powers scalable clinical and diagnostic solutions. Rocket Doctor AI operates an AI-enhanced digital health platform and marketplace, often characterized as a "Shopify for physicians," which facilitates virtual health services and empowers medical professionals. Core offerings also include AI-powered clinical training and assessment tools for medical learners, an AI-powered voice assistant for mental health and care support, and advanced AI-powered Clinical Decision Support systems. The company focuses on delivering high-quality, accessible healthcare solutions throughout North America.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Share Issue/Capital Change Classification · 87% confidence The document is a corporate news release announcing the automatic conversion of special warrants into common shares and warrants, and describes a prospectus supplement to a shelf prospectus to qualify the distribution of these securities. This is clearly an announcement of a share issuance/capital structure change rather than an earnings report, meeting materials, or legal filing. It fits the definition for Share Issue/Capital Change (SHA).
2024-12-24 English
Consent letter of issuer's legal counsel.pdf
Regulatory Filings Classification · 70% confidence The document is a legal opinion/consent letter from McMillan LLP addressed to Canadian securities regulators in connection with a shelf prospectus supplement for Treatment.com AI Inc. It is not a financial report, earnings release, proxy statement, or management discussion. It serves as a regulatory filing in support of a securities offering (the prospectus supplement), but does not itself announce financing terms or report financial results. There is no specific category for a prospectus consent letter, so it falls under the general Regulatory Filings fallback.
2024-12-21 English
Prospectus (non pricing) supplement (other than ATM) – English.pdf
Capital/Financing Update Classification · 90% confidence The document is clearly a prospectus supplement together with a short-form base shelf prospectus for a public distribution of securities (common shares and warrants). It lays out the terms of the special warrant financing, plan of distribution, use of proceeds, risk factors, etc. This is not an earnings release, annual report, or management discussion; rather, it is the primary financing document enabling a capital raise. Under our taxonomy, such a detailed prospectus for raising capital falls under Capital/Financing Update (Code: CAP).
2024-12-21 English
Material change report - English.pdf
Share Issue/Capital Change Classification · 82% confidence The document is a Form 51-102F3 Material Change Report under Canadian securities rules announcing the grant of stock options and restricted share units to executive officers, directors and consultants. This represents a change in the company's capital structure (future issuance of equity instruments). It is not an earnings release, management discussion, or director deal (no insider sale/purchase), nor is it a simple report publication announcement. It is best classified as a Share Issue/Capital Change announcement (SHA).
2024-12-13 English
News release - English.pdf
Share Issue/Capital Change Classification · 85% confidence The document is a corporate press release announcing the grant of stock options and restricted share units to executive officers, directors and consultants under the company’s share compensation plans. This constitutes an issuance of equity instruments and a change in capital structure. It is not a full financial report, nor a management change announcement, insider trading report, or dividend notice. Therefore it fits the Share Issue/Capital Change category.
2024-12-12 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2024-11-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.